Previous 10 | Next 10 |
VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting Phase 1b study in MYC-Driven relapsed/refractory aggressive lymphomas and advanced solid tumors ongoing PALO ALTO, Calif., June 04, 2021 (GLOB...
VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting Phase 1b study in MYC-Driven relapsed/refractory aggressive lymphomas and advanced solid tumors ongoing PALO ALTO, Calif., June 04, 2021 (GLOB...
Vincerx Pharma (VINC) announces that the first patient has been dosed in the company’s Phase 1b study of VIP152 in MYC-driven relapsed or refractory ((R/R)) aggressive lymphomas and advanced solid tumors.The ongoing Phase 1b expansion, first-in-human ((FIH)) study is in patients w...
PALO ALTO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that the first patient has been dosed in the...
PALO ALTO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx’s Chief Business Officer,...
Vincerx Pharma (VINC): Q1 GAAP EPS of -$0.46.Cash and cash equivalents of $53.4MPress Release For further details see: Vincerx Pharma reports Q1 results
Phase 1b dose escalation study of VIP152 in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021 First patient in Phase 1b Study of VIP152 in MYC-driven R/R aggressive lymphomas and advanced solid tumors expected 2Q 2021 P...
PALO ALTO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) (the “Company”), today announced the completion of its redemption event with respect to its outstanding public warrants (the “Public Warrants”). The Company issued a pre...
Dose escalation study in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021 Vincerx’s second clinical program for potential best-in-class CDK9 inhibitor First patient in Phase 1b Study in MYC-driven R/R aggressive...
VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models First-in-human studies on track for 1H 2022 PALO ALTO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) is a biopharmaceutical company a...
News, Short Squeeze, Breakout and More Instantly...
Vincera Pharma Inc Com Company Name:
VINC Stock Symbol:
NASDAQ Market:
Vincera Pharma Inc Com Website:
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The National Institutes of Health (NIH) and Vincerx announced positive result...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,000,000 shares of common stock,...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warra...